Immunotherapy with radiation for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new combination treatment for people with advanced HER2-negative breast cancer. It uses an immunotherapy drug (PD-L1 inhibitor) with radiation therapy, and sometimes a supplement called ursodeoxycholic acid, to see if it helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have breast cancer that has come back or spread to other parts of the body (recurrent or metastatic).
- Your cancer is HER2-negative.
- You have already tried standard treatments for advanced breast cancer.
- You have at least one tumor that can be treated with radiation and another tumor outside that area that can be measured.
- You are feeling well enough to be up and about (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for a type of breast cancer that is hormone receptor-positive (HR+) and HER2-negative. The treatment combines a drug called adebrelimab with chemotherapy, given after a procedure called HIFU (high-intensity focused ultrasound) that uses sound waves to heat and destroy cancer cells. The goal is to see if this combination can improve outcomes before surgery.
This trial tests a new approach for breast cancer that combines a short course of focused radiation (SBRT) with an injection of the immunotherapy drug pembrolizumab directly into the tumor, followed by standard chemotherapy before surgery. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
This study tests a combination of an immunotherapy drug (toripalimab) and a targeted type of radiation called SBRT for breast cancer that didn't shrink with standard chemo. It aims to see if this combination can help your body fight the cancer better.
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy before surgery for people with high-risk, hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this approach can shrink tumors more effectively than chemotherapy alone.
This trial tests a new combination of radiation plus an immunotherapy drug (pembrolizumab) to help your immune system fight metastatic triple-negative breast cancer after a prior immunotherapy has stopped working. The goal is to see if adding radiation can boost your body's response to treatment.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.